Healthcare >> CEO Interviews >> September 29, 2003
DR. GARY A. SHANGOLD is the President and Chief Executive Officer of
NovaDel Pharma Inc., a specialty pharmaceutical company. Dr. Shangold
received a BA cum laude from the University of Pennsylvania in his major
field of Social Behavior. He graduated from Columbia University's
College of Physicians and Surgeons with a Doctor of Medicine degree. He
then completed his residency training in Obstetrics and Gynecology at
the University of Miami (Jackson Memorial Hospital) and a fellowship in
Reproductive Endocrinology at the University of Southern California (Los
Angeles County Medical Center). He is Board-Certified in Obstetrics and
Gynecology and subspecialty-boarded in Reproductive Endocrinology.
Following the completion of his training, Dr. Shangold held the
positions of Assistant Professor and then Associate Professor of
Obstetrics and Gynecology at the University of Chicago Pritzker School
of Medicine. In 1991, he moved from academia into the pharmaceutical
industry as the Medical Director for Obstetrics, Gynecology and
Infertility at Serono Laboratories. He subsequently moved to Johnson &
Johnson as Senior Director of Gynecologic and Reproductive Clinical
Research, and then becoming the Contraception Global Product Team Leader
at the R.W. Johnson Pharmaceutical Research Institute. Later he was
promoted to the position of Vice President and Regulatory Head of Drug
Development at Johnson & Johnson Pharmaceutical Research and
Development, LLC. For the past 11 years, Dr. Shangold has been
affiliated with the Harvard University School of Medicine as Associate
Clinical Professor of Obstetrics, Gynecology and Reproductive Biology
and as a Clinical Associate in the Department of Obstetrics and
Gynecology at Massachusetts General Hospital. Profile
has gone on with the company since you gave an interview last November?
Dr. Shangold: NovaDel is, in many respects,
